Insider Purchases: Inside the Buy

Tag: CFO Insider Buying

Cartoon-style illustration of Ligand Pharmaceuticals' building transforming into a giant molecule, with a Nasdaq bell ringing above and two smiling executives tossing cash into a biotech flask labeled “Royalty Engine.”

Ligand Pharmaceuticals (LGND): In a League of Its Own? Insiders Think So!

Ligand Pharma (LGND) isn’t chasing moonshots—it’s collecting royalties across a sprawling biotech empire. With both the CEO and CFO buying in, and a royalty engine showing 46% revenue growth, insiders may know something. Is this the most compelling quiet biotech turnaround on the Nasdaq?

Read entire article

Tags: BiotechHumor, BiotechInvesting, CEO Buys, CEO insider buying, CEOConfidence, CFO Bought Shares, CFO Insider Buying, CFOBuyIn, ContrarianStocks, Funanc1al, Funanc1al for Investors, Funanc1al Investing, Funanc1alInvesting, InsiderBuys, LGND, LGND Stock, LigandPharma, MoleculeMoney, NasdaqBell, PharmaRoyalties, RoyaltyBiotech, RoyaltyEngine, ScienceStocks, SpeculativeBiotech, TurnaroundPlays, VikingTherapeutics, WallStreetHedgeFunds, ZELSUVMI
Cartoon illustration of Illumina headquarters glowing under a DNA-shaped light beam, with a stock chart climbing in the background and two executives holding shopping bags labeled

🔬 Illumina (ILMN): Let’s Illuminate the Bull Case!

After losing nearly 80% of its value since 2021, Illumina (ILMN) may be ready for a glow-up. CEO Jacob Thaysen and CFO Ankur Dhingra just bought big, and institutional holders are still hanging on. What do they see—and should you see it too?

Read entire article

Tags: Biotech Humor, Biotech Investing, CEO Buys, CEO insider buying, CEOBuyIn, CEOConfidence, CFO Bought Shares, CFO Insider Buying, Contrarian, contrarian investing, Contrarian Play, Contrarian Stocks, ContrarianPlays, DNA Stocks, Funanc1al, Funanc1al for Investors, Funanc1al Investing, Funanc1alInvesting, Future Health Tech, Genomics, Growth Stocks, Illumina, ILMN, ILMN Stock, Innovation Investing, Insider Buys, Science Stocks, Sequencing Stocks, Share buybacks, Turnaround Stocks